Adaptive Biotechnologies (ADPT) Receivables (2018 - 2026)

Adaptive Biotechnologies has reported Receivables for 9 years, with the latest figure at $49.9 million in Q1 2026.

• Quarterly Receivables rose 10.72% year-over-year to $49.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.9 million (up 10.72% YoY) and the FY2025 annual result came in at $51.9 million, up 20.53% from the prior year.
• Receivables fell to $49.9 million in Q1 2026 per ADPT's latest filing, from $51.9 million in the prior quarter.
• Over five years, Receivables peaked at $51.9 million in Q4 2025 and troughed at $23.6 million in Q1 2022.
• A 5-year average of $38.6 million and a median of $40.9 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables soared 117.22% in 2022, then decreased 4.62% in 2023.
• Over 5 years, Receivables stood at $40.9 million in 2022, then fell by 4.62% to $39.0 million in 2023, then advanced by 10.42% to $43.0 million in 2024, then grew by 20.53% to $51.9 million in 2025, then dropped by 3.76% to $49.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $49.9 million, $51.9 million, and $46.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.